Evidence map›Paper›PMID 29228968›Full record

ArticleLipids in health and disease2017

Feces and liver tissue metabonomics studies on the regulatory effect of aspirin eugenol eater in hyperlipidemic rats.

Ning Ma, Xiwang Liu, Xiaojun Kong, Shihong Li, Zenghua Jiao, Zhe Qin, Pengcheng Dong, Yajun Yang, Jianyong Li

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Revealing Probiotic Potential ofFrontiers in microbiology · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ning MaKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China.
Xiwang LiuKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China.
Xiaojun KongKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China.
Shihong LiKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China.
Zenghua JiaoKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China.
Zhe QinKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China.
Pengcheng DongKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China.
Yajun YangKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China. yangyue10224@163.com.
Jianyong LiKey Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, People's Republic of China. lijy1971@163.com.
Chinese Academy of Agricultural Sciences · CNLanzhou Institute of Husbandry and Pharmaceutical Sciences · CN

Funding

National Natural Science Foundation of China No.31402254Natural Science Foundation for Youth of Gansu Province 1506RJYA148
6 · The paper itself

Abstract

backgroundBased on the pro-drug principle, aspirin and eugenol were esterified to synthesize aspirin eugenol ester (AEE). The anti-hyperlipidemia effect of aspirin eugenol ester has been confirmed in hyperlipidemic rat induced by high fat diet (HFD). However, its effect on liver and feces metabonomic profiles remains unknown.

methodsSuspension of AEE was prepared in 5% carboxymethyl cellulose sodium (CMC-Na). Thirty rats were divided into control, model and AEE groups. The control and model rats were fed with normal diet or HFD for 13 weeks, respectively. Rats in AEE-treated group were fed with HFD for 8 weeks to induce hyperlipidemia, and then given AEE once daily by oral gavage for 5 weeks at the dosage of 54 mg/kg body weight. After drug intervention, lipid profile analysis and oil red O staining were carried out to confirm the lipid accumulation in liver tissue. UPLC-Q-TOF/MS-based liver and feces metabonomics coupled with pathway analysis were conducted to evaluate the changes of metabolic profile and endogenous metabolites.

resultsIn liver tissue, oral administration of AEE significantly reduced lipid droplets and the levels of triglyceride (TG) and low-density lipoprotein (LDL). Using principal component analysis (PCA) and partial least squares-discriminate analysis (PLS-DA), distinct changes in metabolite patterns in feces and liver were observed. Liver and feces samples in control, model and AEE groups were scattered in PLS-DA score plots. 28 metabolites in liver and 22 in feces were identified as potential biomarkers related to hyperlipidemia. As possible drug targets, the perturbations of those biomarkers can be regulated by administration of AEE.

conclusionAnti-hyperlipidemia effect of AEE was confirmed by lipid analysis, oil red O staining and metabolomics analysis. The mechanism of AEE might be associated with the changes in the metabolism of glycerophospholipid, amino acid, fatty acid, sphingolipid, purine, bile acid and glutathione.

Indexed as

Administration, OralAmino AcidsAnimalsAspirinBile Acids and SaltsBody WeightCholesterol, LDLDiet, High-FatEugenolFatty AcidsFecesGlycerophospholipidsHyperlipidemiasHypolipidemic AgentsLipid MetabolismLiverAmino AcidsAspirinaspirin eugenol esterBile Acids and SaltsCholesterol, LDLEugenolFatty AcidsGlycerophospholipidsHypolipidemic AgentsPurinesTriglyceridesAspirin eugenol esterBiomarkerHyperlipidemiaMetabonomicUPLC-Q-TOF/MS

Identifiers

PMID29228968
PMCPMC5725792
OpenAlexW2771280267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.